NASDAQ · ARQT
Arcutis Biotherapeutics, Inc.
U.S. listed stock · USD15-minute delay
Find an instrument
- AppleAAPL · NASDAQResearch →
- MicrosoftMSFT · NASDAQResearch →
- NvidiaNVDA · NASDAQResearch →
- AmazonAMZN · NASDAQResearch →
- AlphabetGOOGL · NASDAQResearch →
- Meta PlatformsMETA · NASDAQResearch →
- TeslaTSLA · NASDAQResearch →
- JPMorgan ChaseJPM · NYSEResearch →
- ExxonMobilXOM · NYSEResearch →
- WalmartWMT · NASDAQResearch →
- S&P 500 IndexSPX · S&PResearch →
- Nasdaq 100 IndexNDX · NASDAQResearch →
- Dow Jones Industrial AverageDJI · Dow JonesResearch →
- Cboe Volatility IndexVIX · CboeResearch →
- U.S. Dollar IndexDXY · ICEResearch →
- VIX futuresVX1! · Cboe Futures ExchangeResearch →
- DAX futuresFDAX1! · EurexResearch →
- Euro Stoxx 50 futuresFESX1! · EurexResearch →
- E-mini S&P 500 futuresES1! · CMEResearch →
- E-mini Nasdaq 100 futuresNQ1! · CMEResearch →
- E-mini Dow futuresYM1! · CBOTResearch →
- E-mini Russell 2000 futuresRTY1! · CMEResearch →
- WTI crude oil futuresCL1! · NYMEXResearch →
- Natural gas futuresNG1! · NYMEXResearch →
- Gold futuresGC1! · COMEXResearch →
- Silver futuresSI1! · COMEXResearch →
- Euro FX futures6E1! · CMEResearch →
- Japanese yen futures6J1! · CMEResearch →
- BitcoinBTCUSD · BitstampResearch →
- EtherETHUSD · BitstampResearch →
- Research Any U.S. stock or ETF tickerResearch →
No matching names. Type a U.S. stock ticker (for example MU) to research it.
Loading price chart…
Price chart by TradingView
15-minute delay. Chart times and available timeframes are controlled by the provider.
Earnings
Earnings calendarEarnings announcement for ARQT: Nov 04, 2026
Arcutis Biotherapeutics, Inc. Common Stock is expected to report earnings on 11/04/2026 after market close. The report will be for the fiscal Quarter ending Sep 2026. According to Zacks Investment Research, based on 3 analysts' forecasts, the consensus EPS forecast for the quarter is $0.17. The reported EPS for the same quarter last year was $0.06.
| Fiscal quarter end | Consensus EPS forecast | High | Low | Estimates |
|---|---|---|---|---|
| Sep 2026 | $0.17 | $0.20 | $0.15 | 3 |
| Dec 2026 | $0.22 | $0.39 | $0.03 | 3 |
| Mar 2027 | $0.08 | $0.08 | $0.08 | 1 |
| Jun 2027 | $0.19 | $0.19 | $0.19 | 1 |
Source: Nasdaq, based on Zacks Investment Research consensus estimates. Dates marked as expected may change.
News
Zacks · Fintel · The Motley Fool · RTTNews- Zacks · Oct 29, 9:00 AM EDTSarepta Therapeutics (SRPT) Earnings Expected to Grow: Should You Buy?Sarepta Therapeutics (SRPT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- Fintel · Oct 28, 3:40 PM EDTArcutis Biotherapeutics, Inc. Appoints Dr. Robert Scott to Board of DirectorsOn October 23, 2026, the Board of Directors of Arcutis Biotherapeutics, Inc. increased the authorized number of directors on the Board from ten to eleven directors and appointed Dr. Robert Scott as a new member of the Board and the Nominating and Corporate Governance Committee of
- Zacks · Oct 28, 9:00 AM EDTArcutis Biotherapeutics, Inc. (ARQT) Reports Next Week: Wall Street Expects Earnings GrowthArcutis Biotherapeutics (ARQT) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- Fintel · Oct 15, 8:17 PM EDTCantor Fitzgerald Initiates Coverage of Arcutis Biotherapeutics at OverweightFintel reports that on October 15, 2026, Cantor Fitzgerald initiated coverage of Arcutis Biotherapeutics (NASDAQGS:ARQT) with a Overweight recommendation.This initiation occurred on a day when the stock closed at $29.09, following a close of $26.41 on October 14, 2026, the sessio
- The Motley Fool · Oct 12, 7:05 AM EDT2 Stocks That Could Soar in Q4Viking Therapeutics is set to commence key trials for its obesity drug VK2735.
- RTTNews · Oct 9, 8:52 AM EDTArcutis Shares New Dermatology Data On ZORYVE And Steroid Use; Stock Up(RTTNews) – Arcutis Biotherapeutics (ARQT) announced new data on ZORYVE (roflumilast) and real-world research on long-term topical corticosteroid use presented at the European Academy of Dermatology and Venereology Congress and the Fall Clinical Dermatology Conference.
- RTTNews · Oct 9, 8:33 AM EDTArcutis Presents ZORYVE Data At Dermatology Meetings; Stock Up(RTTNews) – Arcutis Biotherapeutics (ARQT) announced new data on ZORYVE (roflumilast) and research on long-term topical corticosteroid use presented at the EADV Congress and Fall Clinical Dermatology Conference.
- Zacks · Oct 1, 8:55 AM EDTMerck's Tulisokibart Meets Endpoints in Hidradenitis Suppurativa StudyMRK's tulisokibart meets the phase IIb HS study's primary endpoint, with high and medium-dose regimens showing superiority over placebo at week 16.
- Zacks · Sep 21, 7:33 AM EDTStrength Seen in Orchestra BioMed Holdings, Inc. (OBIO): Can Its 5.2% Jump Turn into More Strength?Orchestra BioMed Holdings, Inc. (OBIO) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.
- Zacks · Sep 17, 10:48 AM EDTRHHBY's Lunsumio Combo Meets Goal in 2L Follicular Lymphoma StudyRoche's Lunsumio-Revlimid combo meets its study goal in second-line or later follicular lymphoma, improving PFS versus rituximab plus Revlimid.
- Zacks · Sep 17, 10:38 AM EDTArcutis Biotherapeutics (ARQT) Moves 11.2% Higher: Will This Strength Last?Arcutis Biotherapeutics (ARQT) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
- Zacks · Aug 28, 10:58 AM EDTHere's Why You Should Add ARQT Stock to Your Portfolio NowArcutis raises its 2026 revenue guidance as Zoryve gains momentum, expands into younger patients and advances potential new indications.
Stories from Nasdaq.com, including Zacks, The Motley Fool and Barchart. They open on the publisher’s site; AiFs Market does not edit or endorse them.
Company profile
Loading company profile…
Company profile by TradingView
Financials
Loading fundamental data…
Fundamental data by TradingView
More headlines
More stories for Arcutis Biotherapeutics, Inc. from TradingView. Coverage varies.
Loading related news…
Related news by TradingView
Quotes, charts, company information and headlines are supplied by TradingView. Data may be delayed or unavailable. This page is for market research and does not provide investment advice.